Blogs

83 Hepatitis C Studies From AASLD 2018

Posted on by Dr James
27
Dec

For the past 2 decades, Jules Levin at NATAP has done a fantastic job reporting what is presented at all the major scientific meetings on HIV, HBV and HCV around the world.

Here are 83 studies presented at the AASLD 2018 conference that cover the leading edge of Hep C research as it currently stands.

  1. Hepatitis Debrief: The Liver Meeting 2018 – (11/19/18)
  2. DAA HCV Retreatment Studies at AASLD 2018 – (12/07/18)
  3. Changing Cascade of Care for Hepatitis C in the Era of Direct-Acting Antivirals – (11/13/18)
  4. Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C virus-infected patients in the U.S. – (11/13/18)
  5. Disparities in Accessing HCV Care under Medicaid Programs Across the US; Experience from the TRIO Network – (12/10/18)
  6. Universal HCV Screening on the Way? – (11/13/18)
  7. Hepatitis C Risk-Based vs. Universal Screening Among Pregnant Women: Implementation and Cost-Effectiveness Analysis – (11/19/18)
  8. Prevalence of Chronic Hepatitis C Virus Infection US States and District of Columbia, 2013-2016 – (12/10/18)
  9. A REAL WORLD RESISTANCE PROFILE OF VIROLOGIC FAILURES COLLECTED FROM AN INTERNATIONAL COLLABORATION (SHARED) – (12/10/18)
  10. Prevalence of NS3 and NS5A resistance-associated substitutions through European DAA-failures – (12/10/18)
  11. The prevalence of hepatitis C virus NS5A polymorphisms in Europe – (12/10/18)
  12. Endothelial function worsens with hepatitis C direct-acting antiviral treatment despite improvements in systemic measures of inflammation – (11/28/18)
  13. Baseline Polymorphisms and Phylogeographic Analysis of NS3, NS5A, and NS5B in HCV Genotype 1b-Infected Chinese Patients Enrolled in ONYX-1 – (11/28/18)
  14. Clinical Benefits, Economic Savings and Faster Time to HCV Elimination with a Simplified 8-Week Treatment and Monitoring Program in Chronic F0-F3 Naïve Patients in the US – (11/28/18)
  15. Effectiveness and Safety of DAA Treatment for CHC Patients with Previous HCC: A REAL-C Study – (11/28/18)
  16. Drug-Drug Interaction Potential of Glecaprevir/Pibrentasvir Based on Real-World Medication Use in Patients With Chronic Hepatitis C Virus Infection: Data From the German Hepatitis C-Registry (DHC-R) and PAN-Cohort – (11/27/18)
  17. Effectiveness of Sofosbuvir / Velpatasvir in Treating Hepatitis C Virus Infection in Real-world Setting / IDUs, British Columbia – (11/27/18)
  18. GLECAPREVIR/PIBRENTASVIR ADMINISTERED FOR 8 WEEKS RESULTS IN EXCELLENT EFFECTIVENESS AND SAFETY: A REAL-LIFE STUDY ON 639 ITALIAN HCV PATIENTS FROM THE NAVIGATOR LOMBARDIA NETWORK – (11/26/18)
  19. Treatment of Genotype 3 Cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: Real life experience from Italy – (11/26/18)
  20. Improved Short-Term Survival in HCV Seropositive Kidney Transplant Recipients during the DAA Era in the United States – (11/26/18)
  21. Uptake of and factors associated with direct-acting antiviral therapy among patients in the CHeCS, 2014-2017 – (11/26/18)
  22. Risk-Based HCC Surveillance Strategies Using HCC Risk Prediction Models Have Greater Net Benefit Than the Current One-Size-Fits-All Strategy In Patients who Received Antiviral Treatment for HCV – (11/26/18)
  23. Preemptive DAA Therapy in Donor HCV-positive to Recipient HCV-negative Cardiac Transplantation – (11/19/18)
  24. HCV-RNA Is Readily Detectable in Nasal and Rectal Fluids of HCV Patients with High Viremia – (11/19/18)
  25. High SVR in PWID with HCV Despite Imperfect Medication Adherence: Data from the ANCHOR Study – (11/20/18)
  26. The Hepatitis C Continuum of Care for People Who Inject Drugs; Philadelphia, PA – young PWID 8% treated for HCV, older still only 25% – (11/20/18)
  27. Risk of Incident Diabetes in Hepatitis C Patients Following Completion of Direct-acting Antiviral Therapy – (11/19/18)
  28. The impact of HCV SVR from direct acting antiviral and interferon-based treatments on mortality in a large population based cohort study – (11/19/18)
  29. Hepatitis C Risk-Based vs. Universal Screening Among Pregnant Women: Implementation and Cost-Effectiveness Analysis – (11/19/18)
  30. Direct Antiviral Agents after Successfully Treated Early Hepatocellular Carcinoma Improve Survival in Cirrhotic Patients with Chronic Hepatitis C – (11/19/18)
  31. Sustained Virologic Response Reduces the Incidence of Extrahepatic Manifestations in Chronic Hepatitis C Infection – (11/16/18)
  32. Impact of Baseline HCV RNA Levels as Assessed by 2 Different Assays on the Efficacy of 8-Week Glecaprevir/Pibrentasvir in Patients With HCV GT1-6 Infection – (11/16/18)
  33. Risk of Cardiovascular Disease Events after HCV Treatment: Results from ERCHIVES – (11/16/18)
  34. Effectiveness of 8-week glecaprevir/pibrentasvir(G/P) for treatment naïve, non-cirrhotic patients with HCV infection in the TRIO Health network – (11/16/18)
  35. Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Prior Treatment Failures with Glecaprevir/Pibrentasvir (G/P) in Chronic Hepatitis C Infection – (11/16/18)
  36. REAL-WORLD SAFETY AND EFFECTIVENESS OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR AND GLECAPREVIR/PIBRENTASVIR IN HEPATITIS C INFECTED PATIENTS – (11/16/18)
  37. HEPATITIS C VIRUS REINFECTION AND INJECTING RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR TREATMENT IN PARTICIPANTS ON OPIATE AGONIST THERAPY: C-EDGE CO-STAR PART B – (11/16/18)
  38. Pharmacokinetics of Once-Daily Sofosbuvir or Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 3-<6 Years – (11/16/18)
  39. Ledipasvir/Sofosbuvir for 12 Weeks Is Safe and Effective in Children 3 to <6 years old with Chronic Hepatitis C Virus Infection – (11/16/18)
  40. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With Chronic HCV Infection and Moderate to Severe Renal Impairment: An Integrated Analysis – (11/16/18)
  41. Durability of Sustained Virologic Response and Liver-Related Safety in Patients Treated With Glecaprevir/Pibrentasvir: A Long-Term Follow-Up Study – (11/16/18)
  42. Sofosbuvir / Velpatasvir / Voxilaprevir in DAA Failure Patients with Cirrhosis. Final Results of the French Compassionate Use Program – (11/16/18)
  43. Retreatment with voxilaprevir/velpatasvir/sofosbuvir in patients with chronic hepatitis C virus infection and prior DAA failure – results from the German Hepatitis C-Registry (DHC-R) – (11/16/18)
  44. Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results From a Phase 3 Clinical Trial – (11/16/18)
  45. High SVR in PWID with HCV Despite Imperfect Medication Adherence: Data from the ANCHOR Study updated – (11/16/18)
  46. Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results From a Phase 3 Clinical Trial – (11/19/18)
  47. Incidence and Predictors of de Novo Hepatocellular Carcinoma Following Achievement of Sustained Virologic Response With Direct-Acting Antivirals: Results From the Gilead SVR and Cirrhosis Registries – (11/14/18)
  48. Retreatment with SOF/VEL/VOX in Treatment-Experienced Patients with and without HIV: The RESOLVE Study – (11/14/18)
  49. Effectiveness of Elbasvir/Grazoprevir in Black Persons With Genotype 1 Hepatitis C Virus – (11/14/18)
  50. Efficacy and Safety of Elbasvir/Grazoprevir for 8 or 12 Weeks in Participants With Hepatitis C Virus Genotype 4 Infection – (11/14/18)
  51. Utilization and Effectiveness of Elbasvir/Grazoprevir for the Treatment of Hepatitis C Virus Genotype 1b Infection: Updated Cohort From the US Veteran Affairs Healthcare System – (11/14/18)
  52. Sofosbuvir/Velpatasvir for Patients With Chronic Genotype 3 HCV Infection With Compensated Cirrhosis: an Integrated Analysis of Phase 2 and Phase 3 Clinical Trials – (11/14/18)
  53. Effectiveness of Sofosbuvir/Velpatasvir for 12 Weeks in HCV Genotype 3 Patients with Compensated Cirrhosis in Clinical Practice Cohorts from Around the World – (11/14/18)
  54. Sustained Viral Response Following Treatment With Direct-Acting Antiviral Regimens Is Durable in More Than 6600 Patients: Results of the Gilead Sustained Virologic Response Registry Study – (11/14/18)
  55. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 – (11/14/18)
  56. Response-Guided Therapy with DAA Shortens Treatment Duration in 50% of HCV Treated Patients – (11/14/18)
  57. Early Treatment with Direct-Acting Antivirals Saves Medical Costs in Non-Cirrhotic Patients with Chronic Hepatitis C Virus Infection in the United States – (11/14/18)
  58. Nivolumab in Patients With Child-Pugh B Advanced Hepatocellular Carcinoma in the CheckMate040 Study – (11/13/18)
  59. Changes in the characteristics of hepatitis C patients treated with direct-acting antivirals from 2014-2017 – (11/13/18)
  60. Short-Duration Sofosbuvir/Velpatasvir Safe and Effective in Treating HCV Infection Immediately After Liver Transplant – (11/13/18)
  61. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5 or 6 Infection: Final Results of the ENDURANCE-5,6 Study – (11/13/18)
  62. Changing Cascade of Care for Hepatitis C in the Era of Direct-Acting Antivirals – (11/13/18)
  63. Quality of Life in Patients with Psychiatric Disorders: Pooled Analysis from Glecaprevir/Pibrentasvir Registrational Studies – (11/13/18)
  64. Real-World Effectiveness of Glecaprevir/Pibrentasvir in 1,941 Patients with Hepatitis C Genotypes 1 through 4 – (11/13/18)
  65. Lower Likelihood of Graft Failure and Death after Liver Transplantation in the Era of Current Direct Acting Antivirals: An Analysis of the 2002-2018 United Network for Organ Sharing Registry – (11/13/18)
  66. Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C virus-infected patients in the U.S. – (11/13/18)
  67. High efficacy of glecaprevir/pibrentasvir in patients with chronic HCV GT1 infection who failed prior treatment with NS5A-inhibitor plus sofosbuvir regimens – (11/13/18)
  68. Sofosbuvir/Velpatasvir for 12 Weeks Is Safe and Effective in Patients Undergoing Dialysis – (11/13/18)
  69. The impact of HCV SVR from direct acting antiviral and interferon-based treatments on mortality in a large population based cohort study – (11/13/18)
  70. PRELIMINARY EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 1-6 INFECTION AND COMPENSATED CIRRHOSIS: THE EXPEDITION-8 STUDY – (11/13/18)
  71. Real World Effectiveness of Sofosbuvir/velpatasvir/voxilaprevir in 573 Treatment-Experienced Patients with Hepatitis C – (11/13/18)
  72. High SVR in PWID with HCV Despite Imperfect Medication Adherence: Data from the ANCHOR Study – (11/13/18)
  73. Retreatment with SOF/VEL/VOX in Treatment-Experienced Patients with and without HIV: The RESOLVE Study – (11/13/18)
  74. Incidence of Hepatocellular Carcinoma Among Patients With Hepatitis C Virus Infection Following Treatment With a Grazoprevir-Containing Regimen – (11/13/18)
  75. Real-World Impact of Resistance-Associated Substitutions on Re-Treatment after Ledipasvir/Sofosbuvir Virologic Failure in Hepatitis C Patients (VA) – (11/13/18)
  76. The Medicines Patent Pool Signs Licence with AbbVie to Expand Access to Key Hepatitis C Treatment, Glecaprevir/Pibrentasvir – (11/13/18)
  77. Universal HCV Screening on the Way? – (11/13/18)
  78. Real-life effectiveness and safety of velpatasvir/sofosbuvir/voxilaprevir for previously DAA treated patients with chronic hepatitis C – (11/13/18)
  79. Sofosbuvir/velpatasvir/voxilaprevir(SOF/VEL/VOX) in care of chronic hepatitis C patients; clinical practice experience from the TRIO network – (11/13/18)
  80. Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection: Updated Real-World Data From the German Hepatitis C-Registry – (11/11/18)
  81. National Estimates for HCV Screening and Diagnosis Rates in the United States (2013-2016) Based on a Large Real-World Dataset – (11/11/18)
  82. National Examination of HCV Linkage to Care in the United States (2013-2016) Based on Large Real-World Dataset – (11/09/18)
  83. AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape in the United States Using Comprehensive Dataset – (11/09/18)
dope-on-a-rope.jpg
Dr James

Leave a Reply

× Chat